News
Q2 2025 Management View Jay S. Duker, President and CEO, highlighted "the impressive progress of our Phase III clinical program for our lead asset, DURAVYU, in wet age-related macular degeneration or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback